Table 1.
Descriptive statistics and 12 month changes of clinical endpoints by Vignos status
| Observations in ambulatory participants only | |||||
| Variable | Level | All N = 776 | No Vignos decline | Vignos decline | Adjusted |
| N = 520 | N = 256 | p value | |||
| Steroid status | Non-steroid user | 127 (16.4) | 103 (81.1) | 24 (18.9) | 0.307 |
| Steroid user N (%) | 649 (83.6) | 417 (64.25) | 232 (35.75) | ||
| Age | N | 776 | 520 | 256 | < 0.001 |
| Mean | 9.117 | 8.502 | 10.598 | ||
| Std Err | 0.117 | 0.14 | 0.19 | ||
| 12 month rate of change | N | 754* | 508 | 246 | < 0.001 |
| (m/sec) of10MWT | Mean | –0.159 | –0.05 | –0.398 | |
| Std Err | 0.0147 | 0.016 | 0.023 | ||
| 12 month rate of change | N | 697* | 479 | 218 | < 0.001 |
| (rise/sec) of STS | Mean | –0.02 | –0.012 | –0.039 | |
| Std Err | 0.0026 | 0.003 | 0.004 | ||
| 12 month rate of change | N | 720* | 490 | 230 | < 0.001 |
| (task/sec) of 4SC | Mean | –0.022 | –0.005 | –0.06 | |
| Std Err | 0.0035 | 0.005 | 0.004 | ||
*Participants were required to have a Vignos score at the start and end of each 12-month observation interval, however that requirement did not extend to the TFTs (10MWT, STS, 4SC). The N’s here reflect the number of observations available for modeling and exclude those for which a TFT was unavailable at either the start or end of the 12-month interval.